E2F2 and hepatocellular carcinoma: Notably, AC026401.3 may enhance resistance to sorafenib by interacting with OCT1 and activating the E2F Transcription Factor 2 signaling pathway in hepatocellular carcinoma.[51] High SNHG16 expression is associated with postoperative tumor recurrence and poor prognosis in HCC.